Lung CancerThis is an RSS file. You can use it to subscribe to this data in your favourite RSS reader, such as GoogleReader, or to display this data on your own website or blog. Subscribe to this data using MyMedWorm.Subscribe to this data using GoogleReader.Subscribe to this data using Bloglines.Subscribe to this data using MyYahoo.

This page shows you the latest items in this publication.

613 records returned

ContentsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: Lung Cancer)
Source: Lung Cancer - November 10, 2009 Category: Cancer & Oncology Source Type: journals

Editorial BoardEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: Lung Cancer)
Source: Lung Cancer - November 10, 2009 Category: Cancer & Oncology Source Type: journals

ContentsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: Lung Cancer)
Source: Lung Cancer - October 31, 2009 Category: Cancer & Oncology Source Type: journals

Editorial BoardEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: Lung Cancer)
Source: Lung Cancer - October 31, 2009 Category: Cancer & Oncology Source Type: journals

Treatment of advanced non-small-cell lung cancer in the elderlyEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Abstract: Lung cancer in the older individual is an increasingly common problem faced by the oncologist. Elderly patients have more co-morbidities and tend to tolerate toxic medical treatments more poorly than their younger counterparts. Thus, clinical data obtained in a younger population cannot be automatically extrapolated to the great majority of non-selected elderly patients with non-small-cell lung cancer (NSCLC). The bulk of prospective clinical data regarding chemotherapy and molecularly targeted therapy for elderly NSCLC patients comes from studies in advanced disease.In elderly advanced NSCLC patients single-agen...
Source: Lung Cancer - October 30, 2009 Category: Cancer & Oncology Authors: Cesare Gridelli, Paolo Maione, Antonio Rossi, Marianna Luciana Ferrara, Vincenzo Castaldo, Giovanni Palazzolo, Nicole Mazzeo Tags: Reviews Source Type: journals

Activity of pemetrexed on brain metastases from non-small cell lung cancer: What is the mechanism?Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
We have read the article entitled as ‘Activity of pemetrexed on brain metastases from non-small cell lung cancer’ by Bearz et al., with great interest . It has been reported that pemetrexed had effect on brain metastasis of non-small cell lung cancer (NSCLC), even in those who had not been applied radiotherapy. We consider that this retrospective study with limited number of patients has great importance since it may lead new approaches in brain tumors and metastasis. However, the mechanism is unclear. We have a comment which might contribute to the explanation of the mechanism in the patients who achieved response and...
Source: Lung Cancer - September 25, 2009 Category: Cancer & Oncology Authors: Mutlu Dogan, Bulent Yalcin, Gungor Utkan, Yuksel Urun, Guze Ozal Tags: Correspondence Source Type: journals

May sarcoidal reaction and malignant features co-exist in regional lymph nodes of non-small cell lung cancer patients? Author replyEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
We thank Trisolini et al. for their interest in our manuscript, and their contribution to the literature, with description of a patient in whom transbronchial needle aspiration (TBNA) of a subcarinal lymph node revealed both adenocarcinoma and non-necrotising granulomas . We agree this is significant following our recent publication in which we concluded “Non-necrotising granulomas revealed by EBUS-TBNA of lymph nodes during staging of non-small cell carcinoma (NSCLC) should serve to indicate the absence of lymph node metastases” . (Source: Lung Cancer)
Source: Lung Cancer - September 11, 2009 Category: Cancer & Oncology Authors: Daniel P. Steinfort, Louis B. Irving Tags: Letters to the Editor Source Type: journals

Plasma DNA levels in spiral CT-detected and clinically detected lung cancer patients: A validation analysisEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Biomarker assessment might improve the diagnostic algorithms used for lung cancer screening with low-dose spiral computed tomography (LDSCT) . In previous case–control studies of clinically detected lung cancers, we showed that high levels of free circulating plasma DNA are strongly associated with the presence of lung cancer independently of tumor stage . (Source: Lung Cancer)
Source: Lung Cancer - September 11, 2009 Category: Cancer & Oncology Authors: Luca Roz, Carla Verri, Davide Conte, Rosalba Miceli, Luigi Mariani, Elisa Calabro’, Francesca Andriani, Ugo Pastorino, Gabriella Sozzi Tags: Letters to the Editor Source Type: journals

May sarcoidal reaction and malignant features coexist in regional lymph nodes of non-small cell lung cancer patients?Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
We report on a case of stage IIIA pulmonary adenocarcinoma in which TBNA of a subcarinal node showed the presence of both neoplastic cells and non-necrotizing granulomas. (Source: Lung Cancer)
Source: Lung Cancer - September 7, 2009 Category: Cancer & Oncology Authors: Rocco Trisolini, Alessandra Cancellieri, Marco Patelli Tags: Letters to the Editor Source Type: journals

Results of systemic pemetrexed-based combination chemotherapy versus cytoreductive surgery and hyperthermic intraperitoneal cisplatin and doxorubicin on survival in malignant peritoneal mesotheliomaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
We read with great interest the recent publication by Carteni et al. who reported the results of an International Expanded Access Program that allowed the compassionate use of Pemetrexed (PEM) for patients with malignant peritoneal mesothelioma (MPM) through a pharmaceutical company sponsored and FDA approval scheme. Under this scheme, 109 patients received PEM treatment for MPM. This is by far the largest study of patients receiving systemic chemotherapy for MPM. In 2003, the role of PEM in combination with Cisplatin was established through a Phase III randomized trial that reported a median survival of 12.1 months in the...
Source: Lung Cancer - September 7, 2009 Category: Cancer & Oncology Authors: Akshat Saxena, Terence C. Chua Tags: Letters to the Editor Source Type: journals

Post-operative pulmonary rehabilitation after lung resection for NSCLC: A follow up studyEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
We have previously reported results of our own experience with pulmonary rehabilitation (PR) in pre- and post-operative settings of surgical cohorts of non-small cell lung cancer (NSCLC) patients. (Source: Lung Cancer)
Source: Lung Cancer - September 2, 2009 Category: Cancer & Oncology Authors: A. Cesario, V. Dall’Armi, G. Cusumano, L. Ferri, S. Margaritora, V. Cardaci, S. Cafarotti, P. Russo, L. Paleari, S. Sterzi, F. Pasqua, S. Bonassi, P. Granone Tags: Letters to the Editor Source Type: journals

Cancer stem cell: Implications in cancer biology and therapy with special reference to lung cancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Abstract: The cancer stem cell (CSC) theory is currently central to the field of cancer research, because it is not only a matter of academic interest but also crucial in cancer therapy. CSCs share a variety of biological properties with normal somatic stem cells in terms of self-renewal, the propagation of differentiated progeny, the expression of specific cell markers and stem cell genes, and the utilization of common signaling pathways and the stem cell niche. However, CSCs differ from normal stem cells in their tumorigenic activity. Thus, CSCs are also termed cancer initiating cells. In this paper, we briefly review hi...
Source: Lung Cancer - September 1, 2009 Category: Cancer & Oncology Authors: Hitoshi Kitamura, Koji Okudela, Takuya Yazawa, Hanako Sato, Hiroaki Shimoyamada Tags: Reviews Source Type: journals

ContentsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: Lung Cancer)
Source: Lung Cancer - August 31, 2009 Category: Cancer & Oncology Source Type: journals

Editorial BoardEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: Lung Cancer)
Source: Lung Cancer - August 31, 2009 Category: Cancer & Oncology Source Type: journals

ContentsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: Lung Cancer)
Source: Lung Cancer - August 7, 2009 Category: Cancer & Oncology Source Type: journals

Editorial BoardEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: Lung Cancer)
Source: Lung Cancer - August 7, 2009 Category: Cancer & Oncology Source Type: journals

Prophylactic radiotherapy to intervention sites in mesothelioma: A systematic review and survey of UK practiceEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions: No consensus has been reached to support the use of PIT. However, most centres in the UK still offer PIT. There was widespread interest in a randomised controlled trial to establish PIT efficacy in the era of effective systemic chemotherapy for malignant pleural mesothelioma. (Source: Lung Cancer)
Source: Lung Cancer - July 24, 2009 Category: Cancer & Oncology Authors: Caroline Lee, Neil Bayman, Ric Swindell, Corinne Faivre-Finn Tags: Reviews Source Type: journals

Pemetrexed in the treatment of advanced non-squamous lung cancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Abstract: Pemetrexed, a new cytotoxic agent, is a potent inhibitor of thymidylate synthase and other folate-dependent enzymes. Firstly, pemetrexed was approved in combination with cisplatin for the treatment of malignant pleural mesothelioma. Successively, it has been studied, as single-agent, in phase II and III trials for second-line therapy of non-small cell lung cancer (NSCLC). Based on these results, pemetrexed has been registered for the treatment of recurrent NSCLC. The next step was to test pemetrexed plus cisplatin versus gemcitabine plus cisplatin, as first-line therapy in advanced NSCLC patients, in a phase III,...
Source: Lung Cancer - July 6, 2009 Category: Cancer & Oncology Authors: Antonio Rossi, Serena Ricciardi, Paolo Maione, Filippo de Marinis, Cesare Gridelli Tags: Reviews Source Type: journals

Metastatic potential of lung squamous cell carcinoma associated with HSPC300 through its interaction with WAVE2Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Abstract: The small protein, HSPC300 (haematopoietic stem/progenitor cell protein 300), is associated with reorganization of actin filaments and cell movement, but its activity has not been reported in human cancer cells. Here, we investigated the association of HSPC300 expression with clinical features of lung squamous cell carcinoma. High levels of HSPC300 protein were detected in 84.1% of tumour samples, and in 30.8% of adjacent morphologically normal tissues. The number of primary tumours with elevated HSPC300 levels was significantly higher in primary tumours with lymph node metastases as opposed to those without, and...
Source: Lung Cancer - July 2, 2009 Category: Cancer & Oncology Authors: Xiongwei Cai, Ting Xiao, Sharon Y. James, Jiping Da, Dongmei Lin, Yu Liu, Yang Zheng, Shuangmei Zou, Xuebing Di, Suping Guo, Naijun Han, Yong-Jie Lu, Shujun Cheng, Yanning Gao, Kaitai Zhang Tags: Carcinogenesis and molecular history Source Type: journals

ContentsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: Lung Cancer)
Source: Lung Cancer - June 26, 2009 Category: Cancer & Oncology Source Type: journals

Editorial BoardEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: Lung Cancer)
Source: Lung Cancer - June 26, 2009 Category: Cancer & Oncology Source Type: journals

Closed pleural biopsy to diagnose mesothelioma: Dead or alive?Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Abstract: This letter explores the role of closed pleural biopsy in the diagnosis of malignant mesothelioma. Through retrospective analysis of local data, we found that closed pleural biopsy had a sensitivity of 44% in the diagnosis of malignant mesothelioma. It should therefore still be considered as a first line investigation in suspected mesothelioma especially in centres where CT-guided or thoracoscopic pleural biopsy are not immediately available. (Source: Lung Cancer)
Source: Lung Cancer - June 14, 2009 Category: Cancer & Oncology Authors: Kris M. McLaughlin, Keith M. Kerr, Graeme P. Currie Tags: Correspondence Source Type: journals

ContentsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: Lung Cancer)
Source: Lung Cancer - May 30, 2009 Category: Cancer & Oncology Source Type: journals

Editorial BoardEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: Lung Cancer)
Source: Lung Cancer - May 30, 2009 Category: Cancer & Oncology Source Type: journals

Response to “Serum vascular endothelial growth factor is related to systemic oxidative stress in patients with lung cancer”Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Thank you for providing us with the opportunity to comment on the communication by Kumar et al. The authors are correct indeed in their comment about the discrepancy in the values of VEGF and oxidative stress in patients with Stage IV and M1 disease. The correct values are provided in that follows and we would appreciate it if you provided this in the form of an Erratum to our paper. Bold letters indicate the changes in oxidative stress and VEGF values, as well as the new p-values for comparisons. As noticed, we observed no significant changes in our results after those corrections. We apologize for this inaccuracy. Regard...
Source: Lung Cancer - May 26, 2009 Category: Cancer & Oncology Authors: Alexandra Katsabeki-Katsafli, Theodora Kerenidi, Konstantinos Kostikas, Konstantinos I. Gourgoulianis Tags: Letters to the Editor Source Type: journals

ContentsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: Lung Cancer)
Source: Lung Cancer - May 10, 2009 Category: Cancer & Oncology Source Type: journals

Editorial BoardEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: Lung Cancer)
Source: Lung Cancer - May 10, 2009 Category: Cancer & Oncology Source Type: journals

Angiogenin is involved in lung adenocarcinoma cell proliferation and angiogenesisEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Abstract: Angiogenin, a basic heparin-binding protein, has been shown to play a key role in tumor growth and angiogenesis. It was found in the present study that 67 out of 100 lung adenocarcinomas exhibited angiogenin nuclear expression, and this nuclear expression correlated with vascular and pleural invasion as well as positive lymph node metastasis. To down-regulate angiogenin expression, we constructed an adenoviral-vector based short hairpin RNA system. ELISA, real-time qPCR and immunocytochemical staining demonstrated that adenoviral-vector based siRNA decreased angiogenin mRNA level and protein secretion, and inhibi...
Source: Lung Cancer - May 7, 2009 Category: Cancer & Oncology Authors: Yang Yuan, Feng Wang, Xiao-Hong Liu, De-jun Gong, He-zhong Cheng, Sheng-dong Huang Tags: Carcinogenesis and molecular biology Source Type: journals

Second primary lung cancer or double cancer of the aerodigestive tract?Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
In the December 2008 issue of Lung Cancer Lee et al. reported on second primary lung cancer (SPLC) in patients with curatively treated head and neck cancer (HNC) without lymph node metastases. In 51 patients, referred to the pulmonary department for radiological abnormalities and/or symptoms of lung cancer between 1995 and 2005, and prospectively followed until December 2006, the authors detected 42 cases of SPLC. Diagnosed SPLC at the same time or within 6 months of HNC was defined as synchronous and that developed after more than 6 months as metachronous cancer. (Source: Lung Cancer)
Source: Lung Cancer - May 3, 2009 Category: Cancer & Oncology Authors: Lučka Debevec Tags: Letters to the Editor Source Type: journals

Phase II study of ASA404 (vadimezan, 5,6-dimethylxanthenone-4-acetic acid/DMXAA) 1800mg/m2 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Abstract: This single-arm phase II study evaluated the tumor-vascular disrupting agent ASA404 (vadimezan, 5,6-dimethylxanthenone-4-acetic acid/DMXAA) 1800mg/m2 plus standard therapy of carboplatin and paclitaxel in patients with advanced non-small cell lung cancer (NSCLC). This ASA404 dose is 50% higher than that used in previous phase II studies. Thirty patients with histologically confirmed stage IIIb or IV NSCLC previously untreated with chemotherapy received carboplatin AUC 6mg/mlmin plus paclitaxel 175mg/m2 plus ASA404 1800mg/m2 every 21 days for up to six cycles. The addition of ASA404 1800mg/m2 to standard therapy p...
Source: Lung Cancer - April 30, 2009 Category: Cancer & Oncology Authors: Mark J. McKeage, Martin Reck, Michael B. Jameson, Mark A. Rosenthal, David Gibbs, Paul N. Mainwaring, Lutz Freitag, Richard Sullivan, Joachim Von Pawel Tags: Treatment Source Type: journals

Impact of high-dose chemotherapy with autologous hematopoietic stem cell transplantation on small-cell lung cancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Small-cell lung cancer (SCLC) is a distinct clinical and histological entity within the range of lung cancers. Combination chemotherapy remains the cornerstone of treatment for both limited-stage and extensive-stage small-cell lung cancer. With the assistance of autologous hematopoietic stem cell transplantation (ASCT), myeloablative chemotherapy has been applied to treat relapse or resistant SCLC since 1972. ASCT is essentially a method of overcoming the marrow toxicity of high-dose therapy by the infusion of stem cells that repopulate the marrow. However, the effects of high-dose chemotherapy (HDT) with ASCT on small-cel...
Source: Lung Cancer - April 26, 2009 Category: Cancer & Oncology Authors: Jing Wang, Ping Zhan, Jian Ouyang, Bing Chen, Rongfu Zhou, Yonggong Yang Tags: Correspondence Source Type: journals

Various autoantibodies are found in small-cell lung cancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Recently we read an article which stated that an anti-centromere associated protein B (CENP-B) is an effective follow-up marker in small-cell lung cancer (SCLC). However, we think that this article brought up a rather exaggerated conclusion based on only one anti-CENP-B positive case using quotes from previous journals. In addition, we have been studying about autoantibodies in lung cancer through which we experienced relationships of many autoantibodies with SCLC and would like to report them. (Source: Lung Cancer)
Source: Lung Cancer - April 25, 2009 Category: Cancer & Oncology Authors: Do-CiC Mihn, Think-You Kim Tags: Correspondence Source Type: journals

Disseminated intravascular coagulation (DIC) and non-small cell lung cancer (NSCLC): Report of a case and review of the literatureEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Summary: The clinical manifestation of disseminated intravascular coagulation (DIC) as paraneoplastic phenomenon is common in patients with lung cancer (especially in those with non small cell lung cancer).Surprisingly, only few data have been published on the prevalence of this phenomenon. Herein we present the case of a patient with metastatic giant-cell carcinoma of the lung complicated by DIC leading the patient to death. We also review the literature regarding the incidence, the pathogenesis and the therapy of DIC in NSCLC. As more effective therapy for lung cancer becomes available and patients live longer, DIC can b...
Source: Lung Cancer - April 25, 2009 Category: Cancer & Oncology Authors: E. Voulgaris, G. Pentheroudakis, A. Vassou, N. Pavlidis Tags: Case reports Source Type: journals

Imatinib inhibits in vitro proliferation of cells derived from a pleural solitary fibrous tumor expressing platelet-derived growth factor receptor-betaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
We examined the in vitro effects of imatinib (Novartis Pharma AG, Basel, Switzerland) as a possible inhibitor of PDGFR pathway on cells derived from a recurrence of a pleural malignant solitary fibrous tumor (SFT).Primary cell culture was characterised by immunofluorescence. SFT-derived cells were treated with imatinib at different time points. Western blotting for PDGFR-β, phospho-PDGFR-β or smooth muscle actin (SMA) was performed before and after 96h of treatment with imatinib. SFT-derived cells treated with imatinib for 96h showed a dose dependent decrease of Ki67 expression. Results were confirmed by growth curve. We...
Source: Lung Cancer - April 25, 2009 Category: Cancer & Oncology Authors: Marco Prunotto, Martino Bosco, Lorenzo Daniele, Luigia Macri’, Lisa Bonello, Laura Schirosi, Giulio Rossi, Pierluigi Filosso, Baudolino Mussa, Anna Sapino Tags: Case reports Source Type: journals

Risk of cerebral metastases for postoperative locally advanced non-small-cell lung cancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Abstract: Background: Cerebral metastases are the main determining factor in the failure of locally advanced non-small-cell lung cancer (NSCLC) management. Our study assessed the risk factors of brain metastases in patients with postoperative, locally advanced NSCLC. Implications for PCI treatment are discussed.Methods: Two hundred twenty-three patients treated with surgical resection for stage III-N2 NSCLC were retrospective analyzed to elucidate risk factors for development of brain metastases, and to establish a mathematical model.Results: Median survival time for this patient population was 29.5 months. Frequency of br...
Source: Lung Cancer - April 25, 2009 Category: Cancer & Oncology Authors: Si-yu Wang, Xiong Ye, Wei Ou, Yong-bin Lin, Bin-bin Zhang, Hua Yang Tags: Outcomes Source Type: journals

Lung cancer patients who are asymptomatic at diagnosis show favorable prognosis: A Korean Lung Cancer Registry StudyEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions: Adenocarcinoma has grown to be the leading histopathologic type of lung cancer in South Korea. Absence of symptom at diagnosis is a favorable prognostic factor for patients with non-small cell lung cancer. (Source: Lung Cancer)
Source: Lung Cancer - April 25, 2009 Category: Cancer & Oncology Authors: Kwang-Ho In, Yong-Soo Kwon, In-Jae Oh, Kyu-Sik Kim, Maan-Hong Jung, Kwan-Ho Lee, Sun-Young Kim, Jeong-Seon Ryu, Sung-Yong Lee, Eun-Taik Jeong, Sang-Yeub Lee, Ho-Kee Yum, Chang-Geol Lee, Woo-Sung Kim, Jae-Ill Zo, Hojoong Kim, Young-Whan Kim, Se-Kyu Kim, Ja Tags: Outcomes Source Type: journals

Trends in the outcomes for patients with limited stage small cell lung cancer: An analysis of the Surveillance, Epidemiology, and End Results databaseEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Abstract: We used the Surveillance, Epidemiology, and End Results (SEER) database to examine the outcomes of patients with limited stage small cell lung cancer (LS-SCLC) over time and to determine if any trends were present with respect to the publication of significant clinical trials. We assembled a cohort of 6271 patients aged 21 years and older with LS-SCLC diagnosed from 1983 to 1998 and followed through 2005. Potential covariates included patient age at diagnosis, sex, race, year of diagnosis, laterality, tumor size, and location (upper lobe, middle lobe, lower lobe, or main bronchus). In multivariate analysis, older...
Source: Lung Cancer - April 25, 2009 Category: Cancer & Oncology Authors: Brian E. Lally, Ann M. Geiger, James J. Urbanic, Jerome M. Butler, Stacy Wentworth, Michael C. Perry, Lynn D. Wilson, Janet K. Horton, Frank C. Detterbeck, Antonius A. Miller, Charles R. Thomas, A. William Blackstock Tags: Outcomes Source Type: journals

VEGF, TNF-α and 8-isoprostane levels in exhaled breath condensate and serum of patients with lung cancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Abstract: The aim of the present study was to evaluate the levels of VEGF, 8-isoprostane and TNF-α in EBC and serum of patients with primary lung cancer prior to the initiation of any treatment, in order to evaluate their possible diagnostic role. Furthermore, associations between VEGF, 8-isoprostane and TNF-α levels in EBC and serum with clinicopathologic factors were investigated.We enrolled 30 patients with lung cancer (mean age 65.2±10.5 years) and 15 age and gender-matched healthy smokers as controls. Serum and EBC were collected before any treatment. TNF-α, VEGF and 8-isoprostane levels in EBC and serum were anal...
Source: Lung Cancer - April 25, 2009 Category: Cancer & Oncology Authors: Eleftherios Dalaveris, Theodora Kerenidi, Alexandra Katsabeki-Katsafli, Theodoros Kiropoulos, Kalliopi Tanou, Konstantinos I. Gourgoulianis, Konstantinos Kostikas Tags: Clinical correlates Source Type: journals

Malignant peritoneal mesothelioma—Results from the International Expanded Access Program using pemetrexed alone or in combination with a platinum agentEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Abstract: Aim: Peritoneal mesothelioma (PM) has rarely been studied. The Expanded Access Program (EAP) provided access to 109 patients with PM.Methods: This was a nonrandomized, open-label study conducted in chemo-naïve or previously treated patients with PM not amenable to curative surgery. Patients received pemetrexed (PEM) 500mg/m2 alone or with cisplatin (CIS) 75mg/m2 or carboplatin (CARBO) AUC 5 every 21 days, supplemented with standard vitamin B12, folate, and dexamethasone.Results: Response rates (95% CI) for PEM, PEM/CIS, and PEM/CARBO were 12.5% (3.5, 29.0), 20.0% (7.7, 38.6), and 24.1% (10.3, 43.5), respectively...
Source: Lung Cancer - April 25, 2009 Category: Cancer & Oncology Authors: G. Carteni, C. Manegold, G. Martin Garcia, S. Siena, C.C. Zielinski, D. Amadori, Y. Liu, J. Blatter, C. Visseren-Grul, R. Stahel Tags: Treatment Source Type: journals

Carboplatin and pemetrexed in the management of malignant pleural mesothelioma: A realistic treatment option?Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusion: The combination of carboplatin and pemetrexed may be a viable option in the treatment of malignant pleural mesothelioma. (Source: Lung Cancer)
Source: Lung Cancer - April 25, 2009 Category: Cancer & Oncology Authors: Louise Li, Albiruni Ryan Abdul Razak, Andrew Hughes Tags: Treatment Source Type: journals

An expanded access program of erlotinib (Tarceva) in patients with advanced non-small cell lung cancer (NSCLC): Data report from ItalyEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
We report the interim analysis for patients enrolled in the TRUST trial in Italy.Patients and methods: Eligible patients had stage IIIB/IV NSCLC and had failed or were unsuitable for chemotherapy. Erlotinib (150mg/day orally) was given until disease progression or unacceptable toxicity. Patients were monitored monthly.Results: At time of this analysis, data from 651 patients were available. Patient characteristics were: median age 66 years (range 30–87), male 69%, former or current smoker 71%, ECOG PS 0–1 81%, adenocarcinoma histology 52% and stage IV 82%. Erlotinib was administered as first-, second-, third- or other-...
Source: Lung Cancer - April 25, 2009 Category: Cancer & Oncology Authors: Marcello Tiseo, Cesare Gridelli, Stefano Cascinu, Lucio Crinò, Franco Vito Piantedosi, Francesco Grossi, Alba A. Brandes, Roberto Labianca, Salvatore Siena, Domenico Amoroso, Ornella Belvedere, Brunello Valentino, Alessandra Bearz, Paola Venturino, Andre Tags: Treatment Source Type: journals

Third generation triplet cytotoxic chemotherapy in advanced non-small cell lung cancer: A systematic overviewEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Abstract: Background: Previous meta-analysis on three drugs combination for treatment of advanced non-small cell lung cancer (NSCLC) did not demonstrate an improvement in survival, however many of the trials included in this meta-analysis used older and less effective cytotoxic drugs. We conducted this analysis to compare the relative efficacy of third generation triplet therapy with that of standard double therapy in the treatment of advanced NSCLC.Methods: A MEDLINE search was performed using the search terms “lung cancer” and “randomized trials”. Trials not utilizing a third generation cytotoxic chemotherapeutic...
Source: Lung Cancer - April 25, 2009 Category: Cancer & Oncology Authors: Hatem A. Azim, Inas Elattar, Fausto R. Loberiza, Hamdy Azim, Tony Mok, Apar Kishor Ganti Tags: Treatment Source Type: journals

A phase III randomised study comparing concomitant radiochemotherapy as induction versus consolidation treatment in patients with locally advanced unresectable non-small cell lung cancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
In conclusion, chemoradiotherapy with CDDP, GEM and VNR appears feasible as initial treatment or after induction chemotherapy. Consolidation chemoradiotherapy seems less toxic with a better observed response rates and survival although no valid conclusion can be drawn from the comparison of both arms. (Source: Lung Cancer)
Source: Lung Cancer - April 25, 2009 Category: Cancer & Oncology Authors: T. Berghmans, P. Van Houtte, M. Paesmans, V. Giner, J. Lecomte, G. Koumakis, M. Richez, S. Holbrechts, M. Roelandts, A.P. Meert, S. Alard, N. Leclercq, J.P. Sculier Tags: Treatment Source Type: journals

EGFR gene copy number in adenocarcinoma of the lung by FISH analysis: Investigation of significantly related factors on CT, FDG-PET, and histopathologyEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
In conclusion, a high SUVmax on FDG-PET was significantly related to FISH-positive results. A high proportion of GGO, small tumor diameter on CT, and a well-differentiated histopathology were more frequent in FISH-negative adenocarcinomas. (Source: Lung Cancer)
Source: Lung Cancer - April 25, 2009 Category: Cancer & Oncology Authors: Eun-Ah Park, Hyun Ju Lee, Young Tae Kim, Chang Hyun Kang, Keon Wook Kang, Yoon Kyung Jeon, Jin Mo Goo, Chang Hyun Lee, Chang Min Park Tags: Imaging Source Type: journals

Clinical, pathological and thin-section CT features of persistent multiple ground-glass opacity nodules: Comparison with solitary ground-glass opacity noduleEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Summary: Purpose: : To retrospectively compare the clinical, pathological, and thin-section CT features of persistent multiple ground-glass opacity (GGO) nodules with those of solitary GGO nodules.Materials and methods: Histopathologic specimens were obtained from 193 GGO nodules in 136 patients (87 women, 49 men; mean age, 57; age range 33–81). The clinical data, pathologic findings, and thin-section CT features of multiple and solitary GGO nodules were compared by using t-test or Fisher's exact test.Results: Multiple GGO nodules (n=105) included atypical adenomatous hyperplasia (AAH) (n=31), bronchioloalveolar carcinom...
Source: Lung Cancer - April 25, 2009 Category: Cancer & Oncology Authors: Tae Jung Kim, Jin Mo Goo, Kyung Won Lee, Chang Min Park, Hyun Ju Lee Tags: Imaging Source Type: journals

An electronic nose in the discrimination of patients with non-small cell lung cancer and COPDEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusion: VOC-patterns of exhaled breath discriminates patients with lung cancer from COPD patients as well as healthy controls. The electronic nose may qualify as a non-invasive diagnostic tool for lung cancer in the future. (Source: Lung Cancer)
Source: Lung Cancer - April 25, 2009 Category: Cancer & Oncology Authors: Silvano Dragonieri, Jouke T. Annema, Robert Schot, Marc P.C. van der Schee, Antonio Spanevello, Pierluigi Carratú, Onofrio Resta, Klaus F. Rabe, Peter J. Sterk Tags: Diagnosis and pathology Source Type: journals

Clinicopathological analysis of primary lung carcinoma with heterotopic ossificationEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Abstract: Pulmonary heterotopic ossification is an unusual event. The relationship between ossification and lung carcinoma is unclear. The present study analyzed clinicopathological features of primary lung carcinoma with heterotopic ossification. We reviewed 2269 surgically resected primary lung carcinomas and identified 33 with heterotopic ossification, including 15 cases with intratumoral heterotopic ossification (IHO) and 18 cases with extratumoral heterotopic ossification (EHO). All cases with IHO were adenocarcinomas and 10 of 15 (66.6%) cases had confirmed positive mucin staining in the tumor cells. Cases with EHO c...
Source: Lung Cancer - April 25, 2009 Category: Cancer & Oncology Authors: Hidehiko Kuribayashi, Koji Tsuta, Eiki Mizutani, Akiko Miyagi Maeshima, Yukihiro Yoshida, Akihiko Gemma, Shoji Kudoh, Hisao Asamura, Yoshihiro Matsuno Tags: Diagnosis and pathology Source Type: journals

Aberrant methylation of tumour-related genes in thymic epithelial tumoursEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions: Aberrant DNA methylation was more frequent in thymic carcinoma than in thymoma, and the frequency of DNA methylation in thymic epithelial tumours is roughly parallel to their malignant behaviour. (Source: Lung Cancer)
Source: Lung Cancer - April 25, 2009 Category: Cancer & Oncology Authors: Yukiko Hirose, Kazuya Kondo, Hiromitsu Takizawa, Taeko Nagao, Yasushi Nakagawa, Haruhiko Fujino, Hiroaki Toba, Koichiro Kenzaki, Shoji Sakiyama, Akira Tangoku Tags: Diagnosis and pathology Source Type: journals

Solitary and multiple resected adenocarcinomas after CT screening for lung cancer: Histopathologic features and their prognostic implicationsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions: The proportion of BAC component was a positive prognostic factor and correlated with CT consistency. Contrary to staging predictions, cases of non-solitary node-negative adenocarcinoma had the same excellent prognosis as solitary node-negative cases, suggesting that most of the small, node-negative multiple carcinomas probably represent multiple primaries rather than intrapulmonary metastasis. (Source: Lung Cancer)
Source: Lung Cancer - April 25, 2009 Category: Cancer & Oncology Authors: Madeline Vazquez, Darryl Carter, Elizabeth Brambilla, Adi Gazdar, Masayuki Noguchi, William D. Travis, Yao Huang, Lijuan Zhang, Rowena Yip, David F. Yankelevitz, Claudia I. Henschke, The International Early Lung Cancer Action Program Investigators Tags: Diagnosis and pathology Source Type: journals

Functional inactivation of NF2/merlin in human mesotheliomaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Abstract: The tumor suppressor merlin is encoded by the neurofibromatosis type 2 gene (NF2) which is located on chromosome 22q12 and mutations in this gene have been found in 40% of mesothelioma. Mutations including deletions and insertions lead to truncated and inactivated merlin. Experimental animal models indicate that disruption of the NF2 signalling pathway, together with a deficiency in ink4a, is essential for mesothelioma development. Our hypothesis was that in human mesothelioma without detectable NF2 mutations, regulators of NF2/merlin activity such as CPI-17 would be altered. CPI-17 is an oncogene inhibiting the ...
Source: Lung Cancer - April 25, 2009 Category: Cancer & Oncology Authors: Claudio Thurneysen, Isabelle Opitz, Stefanie Kurtz, Walter Weder, Rolf A. Stahel, Emanuela Felley-Bosco Tags: Carcinogenesis and molecular biology Source Type: journals